Drugs and FDA
Celldex stops developing barzolvolimab for eczema after Phase 2 setback
Celldex will stop developing barzolvolimab for eczema after a Phase 2 study failed to meet the company's internal hurdle rate.

Celldex Therapeutics will stop developing barzolvolimab as an eczema treatment after the drug did not meet the company's internal hurdle rate in a Phase 2 study, the company said, according to BioPharma Dive. Endpoints News reported that the monoclonal antibody failed to reduce itching in patients with eczema compared with placebo.
Celldex is continuing development of barzolvolimab for chronic spontaneous urticaria, a form of chronic hives. BioPharma Dive reported that the drug succeeded in two late-stage trials for that condition and that Celldex is planning an approval filing. The eczema setback follows Phase 2 results in two other immune conditions that also fell short, the outlet reported. Wall Street analysts described the eczema result as immaterial to their investment view, according to BioPharma Dive.


